Operator: Good afternoon, ladies and gentlemen, and welcome to the OmniAb, Inc., Fourth Quarter and Full Year of 22 Earnings Conference Call. At this time all lines are in a listen-only mode.
EMERYVILLE, Calif. (BUSINESS WIRE) Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that on April 8, 2022, the Human Capital Management and Compensation Committee of Ligand’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 40,000 shares of its common stock.